Literature DB >> 8095321

[The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients].

A Besset1, M Tafti, E Villemin, M Billiard.   

Abstract

CNS stimulants are the most widely used drugs to treat narcolepsy which is characterized by the excessive daytime sleepiness and typically associated with cataplexy. However, a number of side effects may often arise with this therapeutic approach. Thus, investigating new drugs which are efficient but well tolerated is of utmost importance in the treatment of narcolepsy. Although modafinil, an alpha-1 adreno-receptor agonist, has been reported to bring substantial awakening properties in animals, the studies performed in man, particularly in narcoleptic subjects, are few. In the present study, we evaluated the effects of a 300 mg daily dose of modafinil on sleepiness and psychomotor performance of 16 narcoleptic subjects. The major effect of modafinil in narcoleptic subjects was a decrease of daytime sleepiness and corresponding improvement of performances involving attentive functions. However, the learning effect in psychomotor tests may mask the drug effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095321     DOI: 10.1016/s0987-7053(05)80282-5

Source DB:  PubMed          Journal:  Neurophysiol Clin        ISSN: 0987-7053            Impact factor:   3.734


  9 in total

1.  Sleepiness is not the inverse of alertness: evidence from four sleep disorder patient groups.

Authors:  Henry J Moller; Gerald M Devins; Jianhua Shen; Colin M Shapiro
Journal:  Exp Brain Res       Date:  2006-04-22       Impact factor: 1.972

2.  Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission.

Authors:  C Sebban; X Q Zhang; B Tesolin-Decros; M J Millan; M Spedding
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.

Authors:  James J Mahoney; Brian J Jackson; Ari D Kalechstein; Richard De La Garza; Lee C Chang; Thomas F Newton
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-04       Impact factor: 5.176

Review 4.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

5.  EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

Authors:  Michael T Saletu; Peter Anderer; Gerda M Saletu-Zyhlarz; Magdalena Mandl; Oliver Arnold; Dorothea Nosiska; Josef Zeitlhofer; Bernd Saletu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

6.  Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach.

Authors:  Philippe Lehert; Cassandra Szoeke
Journal:  Drugs Context       Date:  2020-07-08

7.  Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.

Authors:  Florian Chapotot; Ross Pigeau; Frédéric Canini; Lionel Bourdon; Alain Buguet
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

Review 8.  Narcolepsy in the older adult: epidemiology, diagnosis and management.

Authors:  Sangeeta S Chakravorty; David B Rye
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Multiple treatment comparison in narcolepsy: a network meta-analysis.

Authors:  Philippe Lehert; Bruno Falissard
Journal:  Sleep       Date:  2018-12-01       Impact factor: 5.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.